Abstract:Background: Conditional approvals, also known as accelerated approvals, have been introduced by many pharmaceutical regulators around the world, allowing innovative drugs to enter the market earlier on the basis of limited evidence. This research aims to systematically analyze and compare the post-marketing requirements for conditional approvals of oncology drugs in China and the United States. By collecting and categorizing different types of post-marketing requirements, this study seeks to elucidate how these requirements are proposed and discern the underlying logic and patterns. Methods: This study delved into oncology drug approvals, encompassing FDA accelerated approvals (up to December 31, 2022) and NMPA conditional approvals (from 2017 to December 31, 2022). Leveraging review documents from FDA and NMPA, comprehensive data on product characteristics, all post-marketing commitments and requirements, and especially those related to confirmatory requirements were extracted. The analysis incorporated descriptive statistics, visualizations such as Upset plots, and thorough examination of confirmatory requirement timeframes. Findings: This study examined 168 FDA accelerated approvals and 41 NMPA conditional approvals for oncology indications. Post-marketing requirements displayed diversity: FDA emphasized confirmatory studies, clinical pharmacology studies, and more, while NMPA predominantly focused on confirmatory studies. Confirmatory requirement timeframes indicated higher FDA-required completion times for new confirmatory trials compared to continued completion of original pivotal trials. In contrast, NMPA's requirement patterns were comparatively singular, with relatively fixed timeframes. FDA's evolving trend showed decreasing timeframes over time, suggesting an increasing demand for timely confirmatory data. Interpretation: Conditional approvals offer a unique approach to bring potentially life-saving drugs to the market faster, despite limited supporting evidence. Our analysis of oncology drug conditional approvals in the U.S. and China reveals diverse post-marketing requirement patterns. This study provides valuable insights for regulatory decision-making in a dynamic pharmaceutical landscape. Balancing the risks and rewards of conditional approvals is crucial in ensuring both patient safety and timely access to innovative treatments.

Combining evidence from clinical trials in conditional or accelerated approval

New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials

Beyond the two‐trials rule

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Analysis of post-marketing requirements for oncology drug conditional approvals in the United States and China

Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance from a Cross-pharma Working Group

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Bayesian Approach for Design and Analysis of Medical Device Trials in the Era of Modern Clinical Studies

Incorporating Historical Information to Improve Phase I Clinical Trials

Generating the right evidence at the right time: Principles of a new class of flexible augmented clinical trial designs

Progress and Challenges of the New Conditional Approval Process in China: A Pooled Analysis From 2018 to 2021

Adaptive dose-response studies to establish proof-of-concept in learning-phase clinical trials

A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome

Health Utility Adjusted Survival: a Composite Endpoint for Clinical Trial Designs

Design of randomized clinical trials with a binary endpoint: Conditional versus unconditional analyses of a two‐by‐two table

Covariate-adjusted Group Sequential Comparisons of Survival Probabilities

Changing interim monitoring in response to internal clinical trial data

Simultaneous Confidence Intervals for Signal Detection and Ascertaining Precision of Adverse Event Rates in Clinical Trials

A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies